Slide 1: Dexcom earnings Q3 2024
bpexcom Dexcom earnings ; A / UE WN Q3 2024 My igiobet > RS |
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains “forward-looking statements” that are based on our management’s beliefs and assumptions and on information available to management as of October 24, 2024. We intend for such forward-looking statements to be covered by the safe harbor provisions for fo
Slide 3: Third quarter 2024
Third quarter 2024 Key Financial Strategic $994.2 million in revenue Highlights Highlights 3% organic revenue1 growth over Q3’23 Executed $750 million share Launched Stelo, the first over-the- (-2% US; 16% INT’L2) repurchase program counter glucose biosensor in the US Continued expansion of Dexcom O
Slide 4: Third quarter performance
Third quarter performance Total Revenue & Organic Growth Rate*1 Non-GAAP Gross Profit and Margin* ($MM) 1 ($MM) $1,200 $975 $1,035 $1,004 $994 $750 $630 $664 $638 $921 $569 $626 $1,000 $600 $800 $450 $600 $400 $300 $200 +26% +26% +25% +16% +3% $150 64.7% 64.2% 61.8% 63.5% 63.0% $0 $0 Q3'23 Q4'23 Q1'
Slide 5: 2024 Guidance as of October 24, 2024
2024 Guidance as of October 24, 2024 2024 Annual Revenue and Profitability Guidance Non-GAAP Non-GAAP Adjusted Revenue Gross Profit Margin* Operating Margin* EBITDA Margin * 1 Key Considerations • Extending momentum of 2023 launch in type 2 basal and non-insulin hypo USD populations ~4.000-4.050 ~63
Slide 6: Appendix
Appendix Revenue Data and GAAP Reconciliations
Slide 7: Itemized Reconciliation between GAAP and Non-GAAP Financial Measures
DexCom, Inc. Itemized Reconciliation between GAAP and Non-GAAP Financial Measures Three Months Ended September 30, Three Months Ended September 30, (In millions) 2024 2023 (In millions, except per share data) 2024 2023 GAAP gross profit $ 593.8 $ 623.3 GAAP net income $ 134.6 $ 120.7 Amortization of
Slide 8: Trended Quarterly and Annual Revenue Metrics by Component
DexCom, Inc. Trended Unaudited Quarterly and Annual Revenue Related Metrics by Component Total Company 2022 - 2024 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 YTD' 22 YTD' 23 YTD' 24 Revenue Metrics By Component Sensor & Other Revenue (millions) (1) (2) $ 543.2 $ 597.7 $ 666.6
Slide 9: Trended Quarterly and Annual Revenue Metrics by Geography
DexCom, Inc. Trended Unaudited Quarterly and Annual Revenue Related Metrics by Geography Total Company 2022 - 2024 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 YTD' 22 YTD' 23 YTD' 24 Revenue Metrics By Geography US Revenue (millions) $ 451.2 $ 511.0 $ 573.4 $ 606.4 $ 526.0 $ 61
Slide 10: Trended Quarterly and Annual Organic Revenue Metrics
DexCom, Inc. Trended Unaudited Quarterly and Annual Organic Revenue Metrics Total Company 2022 - 2024 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 YTD' 22 YTD' 23 YTD' 24 Organic Revenue (1) INT'L Revenue - Reported $ 177.6 $ 185.2 $ 196.2 $ 208.8 $ 215.5 $ 254.7 $ 261.4 $ 265.4
Slide 11: Definitions related to Non-GAAP Financial Measures
DexCom, Inc. Definitions related to Non-GAAP Financial Measures Amortization of intangible assets – We are required under GAAP to record the fair values of the intangible assets of the entity on our balance sheet and amortize them over their useful lives. We exclude these non-cash amortization charg